HDAC9 and neoplasm: Although all GBM patients generally receive the same treatment, the molecular characteristics of GBMs are highly diverse, with significant differences in the expression and activity of a number of tumour markers, including differences in HDAC expression levels and differences in expression, concentration and activation of their regulators, as well as targets [16,17].